These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

664 related articles for article (PubMed ID: 17016690)

  • 1. Hypermethylation of Cyclin D2 is associated with loss of mRNA expression and tumor development in prostate cancer.
    Henrique R; Costa VL; Cerveira N; Carvalho AL; Hoque MO; Ribeiro FR; Oliveira J; Teixeira MR; Sidransky D; Jerónimo C
    J Mol Med (Berl); 2006 Nov; 84(11):911-8. PubMed ID: 17016690
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Frequent 14-3-3 sigma promoter methylation in benign and malignant prostate lesions.
    Henrique R; Jerónimo C; Hoque MO; Carvalho AL; Oliveira J; Teixeira MR; Lopes C; Sidransky D
    DNA Cell Biol; 2005 Apr; 24(4):264-9. PubMed ID: 15812243
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MT1G hypermethylation is associated with higher tumor stage in prostate cancer.
    Henrique R; Jerónimo C; Hoque MO; Nomoto S; Carvalho AL; Costa VL; Oliveira J; Teixeira MR; Lopes C; Sidransky D
    Cancer Epidemiol Biomarkers Prev; 2005 May; 14(5):1274-8. PubMed ID: 15894685
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased heparanase expression is caused by promoter hypomethylation and up-regulation of transcriptional factor early growth response-1 in human prostate cancer.
    Ogishima T; Shiina H; Breault JE; Tabatabai L; Bassett WW; Enokida H; Li LC; Kawakami T; Urakami S; Ribeiro-Filho LA; Terashima M; Fujime M; Igawa M; Dahiya R
    Clin Cancer Res; 2005 Feb; 11(3):1028-36. PubMed ID: 15709168
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A quantitative promoter methylation profile of prostate cancer.
    Jerónimo C; Henrique R; Hoque MO; Mambo E; Ribeiro FR; Varzim G; Oliveira J; Teixeira MR; Lopes C; Sidransky D
    Clin Cancer Res; 2004 Dec; 10(24):8472-8. PubMed ID: 15623627
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quantitative assessment of AKAP12 promoter methylation in human prostate cancer using methylation-sensitive high-resolution melting: correlation with Gleason score.
    Liu W; Gong J; Hu J; Hu T; Sun Y; Du J; Sun C; Guan M; Jiang H; Lu Y
    Urology; 2011 Apr; 77(4):1006.e1-7. PubMed ID: 21310466
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Detailed analysis of expression and promoter methylation status of apoptosis-related genes in prostate cancer.
    Carvalho JR; Filipe L; Costa VL; Ribeiro FR; Martins AT; Teixeira MR; Jerónimo C; Henrique R
    Apoptosis; 2010 Aug; 15(8):956-65. PubMed ID: 20464497
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epigenetic regulation of MDR1 gene through post-translational histone modifications in prostate cancer.
    Henrique R; Oliveira AI; Costa VL; Baptista T; Martins AT; Morais A; Oliveira J; Jerónimo C
    BMC Genomics; 2013 Dec; 14():898. PubMed ID: 24344919
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DNA methylation paradigm shift: 15-lipoxygenase-1 upregulation in prostatic intraepithelial neoplasia and prostate cancer by atypical promoter hypermethylation.
    Kelavkar UP; Harya NS; Hutzley J; Bacich DJ; Monzon FA; Chandran U; Dhir R; O'Keefe DS
    Prostaglandins Other Lipid Mediat; 2007 Jan; 82(1-4):185-97. PubMed ID: 17164146
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MicroRNA alteration and putative target genes in high-grade prostatic intraepithelial neoplasia and prostate cancer: STAT3 and ZEB1 are upregulated during prostate carcinogenesis.
    Cha YJ; Lee JH; Han HH; Kim BG; Kang S; Choi YD; Cho NH
    Prostate; 2016 Jul; 76(10):937-47. PubMed ID: 27017949
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aberrant methylation and deacetylation of deleted in liver cancer-1 gene in prostate cancer: potential clinical applications.
    Guan M; Zhou X; Soulitzis N; Spandidos DA; Popescu NC
    Clin Cancer Res; 2006 Mar; 12(5):1412-9. PubMed ID: 16533763
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CpG hypermethylation of the promoter region inactivates the estrogen receptor-beta gene in patients with prostate carcinoma.
    Nojima D; Li LC; Dharia A; Perinchery G; Ribeiro-Filho L; Yen TS; Dahiya R
    Cancer; 2001 Oct; 92(8):2076-83. PubMed ID: 11596023
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CpG hypermethylation of MDR1 gene contributes to the pathogenesis and progression of human prostate cancer.
    Enokida H; Shiina H; Igawa M; Ogishima T; Kawakami T; Bassett WW; Anast JW; Li LC; Urakami S; Terashima M; Verma M; Kawahara M; Nakagawa M; Kane CJ; Carroll PR; Dahiya R
    Cancer Res; 2004 Sep; 64(17):5956-62. PubMed ID: 15342374
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Methylation of cyclin D2 is observed frequently in pancreatic cancer but is also an age-related phenomenon in gastrointestinal tissues.
    Matsubayashi H; Sato N; Fukushima N; Yeo CJ; Walter KM; Brune K; Sahin F; Hruban RH; Goggins M
    Clin Cancer Res; 2003 Apr; 9(4):1446-52. PubMed ID: 12684418
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Promoter methylation of cyclin D2 gene in gastric carcinoma.
    Oshimo Y; Nakayama H; Ito R; Kitadai Y; Yoshida K; Chayama K; Yasui W
    Int J Oncol; 2003 Dec; 23(6):1663-70. PubMed ID: 14612939
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Methylation mediated silencing of TMS1/ASC gene in prostate cancer.
    Das PM; Ramachandran K; Vanwert J; Ferdinand L; Gopisetty G; Reis IM; Singal R
    Mol Cancer; 2006 Jul; 5():28. PubMed ID: 16848908
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inactivation of cyclin D2 gene in prostate cancers by aberrant promoter methylation.
    Padar A; Sathyanarayana UG; Suzuki M; Maruyama R; Hsieh JT; Frenkel EP; Minna JD; Gazdar AF
    Clin Cancer Res; 2003 Oct; 9(13):4730-4. PubMed ID: 14581343
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Down-regulation of drs mRNA in human prostate carcinomas.
    Kim CJ; Shimakage M; Kushima R; Mukaisho K; Shinka T; Okada Y; Inoue H
    Hum Pathol; 2003 Jul; 34(7):654-7. PubMed ID: 12874760
    [TBL] [Abstract][Full Text] [Related]  

  • 19. EFEMP1 as a novel DNA methylation marker for prostate cancer: array-based DNA methylation and expression profiling.
    Kim YJ; Yoon HY; Kim SK; Kim YW; Kim EJ; Kim IY; Kim WJ
    Clin Cancer Res; 2011 Jul; 17(13):4523-30. PubMed ID: 21571867
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytochrome P450 1B1 is overexpressed and regulated by hypomethylation in prostate cancer.
    Tokizane T; Shiina H; Igawa M; Enokida H; Urakami S; Kawakami T; Ogishima T; Okino ST; Li LC; Tanaka Y; Nonomura N; Okuyama A; Dahiya R
    Clin Cancer Res; 2005 Aug; 11(16):5793-801. PubMed ID: 16115918
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.